Our Analysis

Sangamo releasing results of p2b in diabetic neuropathy on Monday morning
Press Release Source: Sangamo BioSciences, Inc. On Friday September 30, 2011, 5:40 pm EDT RICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq:SGMO - News)...
By DavidTannenbaum, Sep 30th, 2011 in Analysis 0
2Q Sangamo Earnings and CC Review
Sangamo today announced results for its 2Q of 2011.  The low revenue indicates that royalties from the 2 ZFP partner programs has still not accelerated.  However, the most important...
By DavidTannenbaum, Jul 27th, 2011 in Earnings 0
Sangamo going to be data rich in the second half of 2011
There are two major catalysts upcoming for Sangamo Biosciences in the second half of 2011: Top-line results from their Phase IIb study in diabetic neuropathy for SB-509 and preliminary results...
By DavidTannenbaum, Jul 25th, 2011 in Analysis 0
Previous Next
Home | Terms Of Service
Copyright © 2012 www.CrushBiotech.com. All rights reserved.